FDA fast tracks Rx for hard-to-treat peripheral T-cell lymphoma
Allos Therapeutics has received accelerated FDA approval for Folotyn (pralatrexate) as a single-agent treatment in patients with relapsed or refractory peripheral T-cell lymphoma.
Allos Therapeutics has received accelerated FDA approval for Folotyn (pralatrexate) as a single-agent treatment in patients with relapsed or refractory peripheral T-cell lymphoma.
The company's new drug application was based on data from the PROPEL trial, which showed positive results for overall response. Improvement in progression-free survival or overall survival has not been demonstrated, according to Allos. The company will perform more studies to verify the clinical benefit of pralatrexate in T-cell lymphoma.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
